These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 19429551)

  • 21. An Engineered Double Lipid II Binding Motifs-Containing Lantibiotic Displays Potent and Selective Antimicrobial Activity against Enterococcus faecium.
    Zhao X; Yin Z; Breukink E; Moll GN; Kuipers OP
    Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32179527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Construction of an expression system for site-directed mutagenesis of the lantibiotic mersacidin.
    Szekat C; Jack RW; Skutlarek D; Färber H; Bierbaum G
    Appl Environ Microbiol; 2003 Jul; 69(7):3777-83. PubMed ID: 12839744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LiaRS reporter assay: A simple tool to identify lipid II binding moieties in lantibiotic nukacin ISK-1.
    Elsayed KM; Islam MR; Abdullah-Al-Mahin ; Nagao JI; Zendo T; Sonomoto K
    J Biosci Bioeng; 2017 Mar; 123(3):398-401. PubMed ID: 27856233
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Posttranslationally modified bacteriocins--the lantibiotics.
    Guder A; Wiedemann I; Sahl HG
    Biopolymers; 2000; 55(1):62-73. PubMed ID: 10931442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-proteinogenic amino acids in lacticin 481 analogues result in more potent inhibition of peptidoglycan transglycosylation.
    Knerr PJ; Oman TJ; Garcia De Gonzalo CV; Lupoli TJ; Walker S; van der Donk WA
    ACS Chem Biol; 2012 Nov; 7(11):1791-5. PubMed ID: 22920239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular Recognition of Lipid II by Lantibiotics: Synthesis and Conformational Studies of Analogues of Nisin and Mutacin Rings A and B.
    Dickman R; Mitchell SA; Figueiredo AM; Hansen DF; Tabor AB
    J Org Chem; 2019 Sep; 84(18):11493-11512. PubMed ID: 31464129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipid II: a central component in bacterial cell wall synthesis and a target for antibiotics.
    de Kruijff B; van Dam V; Breukink E
    Prostaglandins Leukot Essent Fatty Acids; 2008; 79(3-5):117-21. PubMed ID: 19008088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mode of action of the lantibiotic mersacidin: inhibition of peptidoglycan biosynthesis via a novel mechanism?
    Brötz H; Bierbaum G; Markus A; Molitor E; Sahl HG
    Antimicrob Agents Chemother; 1995 Mar; 39(3):714-9. PubMed ID: 7793878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple activities in lantibiotics--models for the design of novel antibiotics?
    Pag U; Sahl HG
    Curr Pharm Des; 2002; 8(9):815-33. PubMed ID: 11945173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elucidation of the antimicrobial mechanism of mutacin 1140.
    Smith L; Hasper H; Breukink E; Novak J; Cerkasov J; Hillman JD; Wilson-Stanford S; Orugunty RS
    Biochemistry; 2008 Mar; 47(10):3308-14. PubMed ID: 18266322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The lantibiotic mersacidin inhibits peptidoglycan synthesis by targeting lipid II.
    Brötz H; Bierbaum G; Leopold K; Reynolds PE; Sahl HG
    Antimicrob Agents Chemother; 1998 Jan; 42(1):154-60. PubMed ID: 9449277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insights into the mode of action of the two-peptide lantibiotic haloduracin.
    Oman TJ; van der Donk WA
    ACS Chem Biol; 2009 Oct; 4(10):865-74. PubMed ID: 19678697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cloning, sequencing and production of the lantibiotic mersacidin.
    Bierbaum G; Brötz H; Koller KP; Sahl HG
    FEMS Microbiol Lett; 1995 Mar; 127(1-2):121-6. PubMed ID: 7737474
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advancing cell wall inhibitors towards clinical applications.
    Maffioli SI; Cruz JC; Monciardini P; Sosio M; Donadio S
    J Ind Microbiol Biotechnol; 2016 Mar; 43(2-3):177-84. PubMed ID: 26515981
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mode of action of lipid II-targeting lantibiotics.
    Bauer R; Dicks LM
    Int J Food Microbiol; 2005 May; 101(2):201-16. PubMed ID: 15862882
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The lantibiotic mersacidin is an autoinducing peptide.
    Schmitz S; Hoffmann A; Szekat C; Rudd B; Bierbaum G
    Appl Environ Microbiol; 2006 Nov; 72(11):7270-7. PubMed ID: 16980420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microtiter plate bioassay to monitor the interference of antibiotics with the lipid II cycle essential for peptidoglycan biosynthesis.
    Burkard M; Stein T
    J Microbiol Methods; 2008 Sep; 75(1):70-4. PubMed ID: 18558445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The biology of lantibiotics from the lacticin 481 group is coming of age.
    Dufour A; Hindré T; Haras D; Le Pennec JP
    FEMS Microbiol Rev; 2007 Mar; 31(2):134-67. PubMed ID: 17096664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination of antibiotic mechanisms in lantibiotics.
    Hoffmann A; Pag U; Wiedemann I; Sahl HG
    Farmaco; 2002 Aug; 57(8):685-91. PubMed ID: 12361237
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mapping the targeted membrane pore formation mechanism by solution NMR: the nisin Z and lipid II interaction in SDS micelles.
    Hsu ST; Breukink E; de Kruijff B; Kaptein R; Bonvin AM; van Nuland NA
    Biochemistry; 2002 Jun; 41(24):7670-6. PubMed ID: 12056898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.